Martin Brown
Publications
- Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013; (5): 1159-60
- Deficiency in mammalian histone H2B ubiquitin ligase Bre1 (Rnf20/Rnf40) leads to replication stress and chromosomal instability. Cancer Res. 2012; (8): 2111-9
- Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A. 2010; (18): 8363-8
- Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010; (3): 694-705
- Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009; (7239): 780-3
- Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008; (3): 193-205
- Imaging tumor sensitivity to a bioreductive prodrug: two for the price of one! Clin Cancer Res. 2012; (6): 1487-9
- Inhibiting homologous recombination for cancer therapy. Cancer Biol Ther. 2012; (2): 61-8
- R-loops and genomic instability in Bre1 (RNF20/40)-deficient cells. Cell Cycle. 2012; (16): 2980-4
- Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys. 2011; (4): 1188-95
- In reply to drs. Koch and evans. Int J Radiat Oncol Biol Phys. 2011; (5): 1605
- Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Res. 2011; (15): 5265-75
- Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. Br J Cancer. 2011; (12): 1805-9
- Deficiency in Bre1 impairs homologous recombination repair and cell cycle checkpoint response to radiation damage in mammalian cells. Radiat Res. 2010; (5): 558-65
- Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol. 2010; (4): 1564-76
- Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys. 2010; (2): 323-7
- DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. Cancer Res. 2009; (9): 3884-91
- Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives. Cell Cycle. 2009; (7): 970-6
- Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis. 2009; (2): 159-64
- A role for Lsmlp in response to ultraviolet-radiation damage in Saccharomyces cerevisiae. Radiat Res. 2008; (4): 411-21
- High-dose single-fraction radiotherapy: exploiting a new biology? Int J Radiat Oncol Biol Phys. 2008; (2): 324-5
- Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res. 2008; (1): 257-65
- In vivo 1H magnetic resonance spectroscopy of lactate in patients with stage IV head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2008; (4): 1151-7
- Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. Cancer Res. 2008; (19): 7995-8003
- Radiosensitization of yeast cells by inhibition of histone h4 acetylation. Radiat Res. 2008; (5): 618-27
- Tumor hypoxia in cancer therapy. Methods Enzymol. 2007: 297-321
- Global analysis of gene function in yeast by quantitative phenotypic profiling. Mol Syst Biol. 2006: 2006.0001
- A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia. Cancer Res. 2005; (14): 6151-8
- Identification of mitogen-activated protein kinase signaling pathways that confer resistance to endoplasmic reticulum stress in Saccharomyces cerevisiae. Mol Cancer Res. 2005; (12): 669-77
- Multiple endonucleases function to repair covalent topoisomerase I complexes in Saccharomyces cerevisiae. Genetics. 2005; (2): 591-600
- The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005; (3): 231-7
- Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004; (6): 437-47
- Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. Cancer Res. 2004; (11): 3940-8
- Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? Cancer Biol Ther. 2003 Sep-Oct; (5): 477-90
- Comment on "Tumor response to radiotherapy regulated by endothelial cell apoptosis" (II). Science. 2003; (5652): 1894; author reply 1894
- Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2003; (2): 375-83
- Evaluation of hypoxia-inducible factor-1alpha (HIF-1alpha) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. Int J Radiat Oncol Biol Phys. 2003; (4): 1184-93
- Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem Pharmacol. 2003; (11): 1807-15
- Similar radiation sensitivities of acutely and chronically hypoxic cells in HT 1080 fibrosarcoma xenografts. Radiat Res. 2003; (1): 94-101
- Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther. 2002 Sep-Oct; (5): 453-8
- Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia. 2002 Jan-Feb; (1): 40-8
- Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 2002; (4): 291-6
- Estimating DNA repair by sequential evaluation of head and neck tumor radiation sensitivity using the comet assay. Arch Otolaryngol Head Neck Surg. 2002; (6): 698-702
- Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes Chromosomes Cancer. 2002; (4): 372-83
- The 93rd Annual Meeting of the American Association for Cancer Research. 6-10 April 2002, San Francisco, California, USA. Expert Opin Pharmacother. 2002; (5): 629-32
- Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res. 2002; (18): 5248-53
- Transcriptional response of Saccharomyces cerevisiae to DNA-damaging agents does not identify the genes that protect against these agents. Proc Natl Acad Sci U S A. 2002; (13): 8778-83
- Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia. 2001 Nov-Dec; (6): 527-34
- A genome-wide screen in Saccharomyces cerevisiae for genes affecting UV radiation sensitivity. Proc Natl Acad Sci U S A. 2001; (22): 12608-13
- An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin. Int J Radiat Oncol Biol Phys. 2001; (1): 175-82
- Apoptosis: mediator or mode of cell killing by anticancer agents? Drug Resist Updat. 2001; (2): 135-6
- Inhibition of DNA replication by tirapazamine. Cancer Res. 2001; (14): 5425-31
- Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem Pharmacol. 2001; (9): 1201-9
- Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys. 2001; (2): 319-26
- An early oxygen-dependent step is required for dexamethasone-induced apoptosis of immature mouse thymocytes. J Immunol. 2000; (9): 4822-30
- Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 2000; (6): 493-8
- Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today. 2000; (4): 157-62
- Hypoxic cytotoxic agents: a new approach to cancer chemotherapy. Drug Resist Updat. 2000; (1): 7-13
- In vivo 1H MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen tension measurements. AJNR Am J Neuroradiol. 2000; (1): 183-93
- Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000; (4): 919-22
- A p53 and apoptotic independent role for p21waf1 in tumour response to radiation therapy. Oncogene. 1999; (47): 6540-5
- Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999; (7): 1391-9
- Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer. 1999; (8): 1245-51
- Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation. Radiat Oncol Investig. 1999; (3): 163-9
- DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia. 1999; (5): 461-7
- Managed care, consolidation among health care providers, and health care: evidence from mammography. Rand J Econ. 1999; (2): 351-74
- Oxygen tension measurements of tumors growing in mice. Int J Radiat Oncol Biol Phys. 1999; (1): 171-80
- The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999; (23): 5863-70
- Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol. 1999: S29-33
- Tissue oxygen distribution in head and neck cancer patients. Head Neck. 1999; (2): 146-53
- Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine. Br J Cancer. 1998: 12-4
- Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers. Laryngoscope. 1998; (12): 1856-60
- The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998; (7): 1408-16
- Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res. 1998; (10): 2098-101
- Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des. 1998; (6): 529-39
- Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem Pharmacol. 1997; (2): 249-57
- Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 1997; (8): 791-6
- Baroreflex dysfunction after nasopharyngectomy and bilateral carotid isolation. Arch Otolaryngol Head Neck Surg. 1997; (4): 434-7
- Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res. 1997; (5): 541-50
- Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res. 1997; (21): 4703-6
- Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol. 1997; (4): 361-6
- NCI's anticancer drug screening program may not be selecting for clinically active compounds. Oncol Res. 1997; (5): 213-5
- Stable translocations detected by fluorescence in situ hybridization: a rapid surrogate end point to evaluate the efficacy of a potentiator of tumor response to radiotherapy. Cancer Res. 1997; (4): 672-7
- Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res. 1997; (14): 2922-8
- Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 1996; (2): 173-8
- Hypoxia-Specific Cytotoxins in Cancer Therapy. Semin Radiat Oncol. 1996; (1): 22-36
- Induction and repair of chromosome aberrations in scid cells measured by premature chromosome condensation. Radiat Res. 1996; (1): 39-46
- The DNA damage response in DNA-dependent protein kinase-deficient SCID mouse cells: replication protein A hyperphosphorylation and p53 induction. Proc Natl Acad Sci U S A. 1996; (24): 13825-30
- Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br J Cancer. 1996; (8): 952-60
- DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science. 1995; (5201): 1178-83
- Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int J Radiat Oncol Biol Phys. 1994; (1): 145-50
- Discrepancies between measured changes of radiobiological hypoxic fraction and oxygen tension monitoring using two assay systems. Int J Radiat Oncol Biol Phys. 1994; (2): 355-61
- Increased cytotoxicity of chronic hypoxic cells by molecular inhibition of GRP78 induction. Int J Radiat Oncol Biol Phys. 1994; (3): 661-6
- Prediction of human cell radiosensitivity: comparison of clonogenic assay with chromosome aberrations scored using premature chromosome condensation with fluorescence in situ hybridization. Int J Radiat Oncol Biol Phys. 1994; (5): 1127-32
- Quantification of two-dimensional NOE spectra via a combined linear and nonlinear least-squares fit. J Biomol NMR. 1994; (5): 645-52
- Radiation-induced damage, repair and exchange formation in different chromosomes of human fibroblasts determined by fluorescence in situ hybridization. Radiat Res. 1994; (1): 34-43
- Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys. 1994; (3): 493-7
- Tumour hypoxia: the picture has changed in the 1990s. Int J Radiat Biol. 1994; (1): 95-102
- Characterization of the DNA double strand break repair defect in scid mice. Cancer Res. 1993; (6): 1244-8
- Chromosomal radiosensitivity at intrachromosomal telomeric sites. Genes Chromosomes Cancer. 1993; (1): 8-14
- Complementation of the radiosensitive phenotype in severe combined immunodeficient mice by human chromosome 8. Cancer Res. 1993; (24): 6011-6
- Lack of differential radiosensitization of hypoxic cells in a mouse tumor at low radiation doses per fraction by cisplatin. Radiat Res. 1993; (2): 252-6
- Mechanism of chromosome exchange formation in human fibroblasts: insights from "chromosome painting". Environ Mol Mutagen. 1993; (4): 218-24
- Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. Br J Cancer. 1993; (2): 321-5
- SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer. 1993; (6): 1163-70
- The influence of irradiation of the tumor bed on tumor hypoxia: measurements by radiation response, oxygen electrodes, and nitroimidazole binding. Radiat Res. 1993; (3): 411-7
- Toxicology of daily administration to mice of the radiation potentiator SR 4233 (WIN 59075). Radiother Oncol. 1993; (1): 79-81
- Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 1993; (19): 4633-6
- Visualization of nonreciprocal chromosome exchanges in irradiated human fibroblasts by fluorescence in situ hybridization. Radiat Res. 1993; (1): 71-6
- Activation of the heat shock transcription factor by hypoxia in normal and tumor cell lines in vivo and in vitro. Int J Radiat Oncol Biol Phys. 1992; (4): 891-7
- Carbogen and nicotinamide: expectations too high? Radiother Oncol. 1992; (2): 75-6
- Characterization of a CHO cell line resistant to killing by the hypoxic cell cytotoxin SR 4233. Int J Radiat Oncol Biol Phys. 1992; (4): 681-4
- Computerized histographic oxygen tension measurements of murine tumors. Adv Exp Med Biol. 1992: 153-9
- Differential expression of protein kinase C epsilon protein in lung cancer cell lines by ionising radiation. Br J Cancer. 1992; (5): 844-9
- Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing. Br J Cancer. 1992; (6): 1053-8
- Fluorescence in situ hybridization: an improved method of quantitating chromosome damage and repair. BJR Suppl. 1992: 61-4
- Improving the effectiveness of the bioreductive antitumor agent SR 4233 by induced hypoxia. Adv Exp Med Biol. 1992: 177-81
- Pharmacological modification of tumor blood flow: lack of correlation between alteration of mean arterial blood pressure and changes in tumor perfusion. Int J Radiat Oncol Biol Phys. 1992; (1): 79-86
- Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 1992; (16): 4473-7
- Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1992; (4): 701-5
- The frequency of translocations after treatment for Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1992; (4): 737-42
- The prediction of human tumor radiosensitivity in situ: an approach using chromosome aberrations detected by fluorescence in situ hybridization. Int J Radiat Oncol Biol Phys. 1992; (2): 279-86
- The use of asymmetric-field inversion gel electrophoresis to predict tumor cell radiosensitivity. Radiother Oncol. 1992; (4): 231-8
- What role do glutathione S-transferases play in the cellular response to ionizing radiation? Int J Radiat Oncol Biol Phys. 1992; (4): 759-63
- Targeting bioreductive drugs to tumours: is it necessary to manipulate blood flow? Int J Radiat Biol. 1991 Jul-Aug; (1-2): 231-6
- Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications. Int J Radiat Biol. 1991; (1): 117-31
- Biochemical evidence for two different mechanisms for bleomycin-induced cell killing. Mutat Res. 1991; (2): 69-75
- Hydralazine does not increase hypoxia in tumors growing in preirradiated tissue. Int J Radiat Oncol Biol Phys. 1991; (6): 1435-40
- SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br J Cancer. 1991; (3): 358-62
- SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother Oncol. 1991: 151-6
- Structure-activity relationships for tumour radiosensitization by analogues of nicotinamide and benzamide. Int J Radiat Biol. 1991; (3): 739-48
- The biodistribution of 111In-anti-bFGF in a variety of tumors. Correlation with cell-binding assays. Ann N Y Acad Sci. 1991: 497-502
- The hypersensitivity of the Chinese hamster ovary variant BL-10 to bleomycin killing is due to a lack of glutathione S-transferase-alpha activity. Cancer Res. 1991; (16): 4463-9
- The use of fluorescence in situ hybridisation combined with premature chromosome condensation for the identification of chromosome damage. Br J Cancer. 1991; (4): 517-21
- Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J Natl Cancer Inst. 1991; (3): 178-85
- Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys. 1991; (3): 457-61
- scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair. Proc Natl Acad Sci U S A. 1991; (4): 1394-7
- Aerobic radiosensitization by SR 4233 in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1990; (1): 125-32
- Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 1990; (24): 7745-9
- The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo. Radiother Oncol. 1990; (1): 49-57
- Tumor hypoxia, drug resistance, and metastases. J Natl Cancer Inst. 1990; (5): 338-9
- Use of fluorescent in situ hybridization to detect chromosomal rearrangements in somatic cell hybrids. Genes Chromosomes Cancer. 1990; (3): 248-51
- Comparison between X-rays and SR 4233 for cytotoxicity and repair of potentially lethal damage in human cells. Int J Radiat Biol. 1989; (5): 813-6
- Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Res. 1989; (20): 5664-70
- In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumor agent. Cancer Res. 1989; (4): 925-9
- Keynote address: hypoxic cell radiosensitizers: where next? Int J Radiat Oncol Biol Phys. 1989; (4): 987-93
- Misonidazole chemosensitization of EMT6 spheroids to melphalan. Radiother Oncol. 1989; (1): 103-14
- Pre- and post-irradiation radiosensitization by SR 4233. Int J Radiat Oncol Biol Phys. 1989; (4): 967-71
- Structure-activity relationships for benzotriazine di-N-oxides. Int J Radiat Oncol Biol Phys. 1989; (4): 977-81
- Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res. 1989; (1): 139-50
- Chemical modification of radiation and chemotherapy. Am J Clin Oncol. 1988; (3): 288-303
- Elevation of intracellular glutathione levels following depletion and its relationship to protection against radiation and alkylating agents. Pharmacol Ther. 1988; (1-3): 293-9
- Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol. 1988; (3): 209-18
- Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys. 1988; (3): 685-90
- Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 1988; (21): 5947-52
- Radiosensitization, thiol oxidation, and inhibition of DNA repair by SR 4077. Radiat Res. 1988; (2): 346-55
- Radiosensitization in multifraction schedules. I. Evidence for an extremely low oxygen enhancement ratio. Radiat Res. 1987; (1): 124-33
- Radiosensitization in multifraction schedules. II. Greater sensitization by 2-nitroimidazoles than by oxygen. Radiat Res. 1987; (1): 134-45
Help
Trial Administration